Humana Inc (NYSE:HUM) – Investment analysts at Piper Sandler lifted their Q2 2020 earnings estimates for shares of Humana in a research report issued on Wednesday, July 8th. Piper Sandler analyst S. James now forecasts that the insurance provider will post earnings per share of $10.07 for the quarter, up from their previous forecast of $6.89. Piper Sandler also issued estimates for Humana’s Q3 2020 earnings at $2.45 EPS, Q4 2020 earnings at $0.70 EPS and Q4 2021 earnings at $2.93 EPS.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share for the quarter, beating the consensus estimate of $4.84 by $0.56. The business had revenue of $18.94 billion for the quarter, compared to the consensus estimate of $18.49 billion. Humana had a return on equity of 21.02% and a net margin of 3.86%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the business posted $4.48 earnings per share.

Several other research firms also recently weighed in on HUM. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating and set a $396.00 target price on the stock. in a research report on Friday, April 17th. ValuEngine cut Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 2nd. Cowen reaffirmed a “market perform” rating and issued a $410.00 price target on shares of Humana in a report on Tuesday, June 16th. They noted that the move was a valuation call. Cantor Fitzgerald increased their price target on Humana from $405.00 to $410.00 in a report on Wednesday, June 17th. Finally, SunTrust Banks increased their price target on Humana from $400.00 to $440.00 and gave the company a “hold” rating in a report on Thursday, May 21st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the stock. Humana presently has an average rating of “Buy” and an average target price of $411.29.

NYSE HUM opened at $381.87 on Monday. The company has a market cap of $50.45 billion, a PE ratio of 19.60, a price-to-earnings-growth ratio of 1.65 and a beta of 0.87. The stock’s 50 day simple moving average is $388.18 and its 200-day simple moving average is $359.01. Humana has a 1-year low of $208.25 and a 1-year high of $412.70. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.66 and a quick ratio of 1.66.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.625 dividend. The ex-dividend date is Monday, June 29th. This represents a $2.50 dividend on an annualized basis and a dividend yield of 0.65%. Humana’s payout ratio is presently 13.99%.

Several hedge funds and other institutional investors have recently modified their holdings of HUM. Norges Bank acquired a new stake in shares of Humana in the fourth quarter valued at $477,049,000. APG Asset Management N.V. grew its stake in shares of Humana by 3,122.6% in the first quarter. APG Asset Management N.V. now owns 1,135,219 shares of the insurance provider’s stock valued at $268,930,000 after buying an additional 1,099,992 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Humana by 507.7% in the first quarter. Jennison Associates LLC now owns 1,256,095 shares of the insurance provider’s stock valued at $394,439,000 after buying an additional 1,049,394 shares in the last quarter. Capital Research Global Investors grew its stake in shares of Humana by 15.2% in the fourth quarter. Capital Research Global Investors now owns 7,829,472 shares of the insurance provider’s stock valued at $2,869,658,000 after buying an additional 1,033,910 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Humana by 257.4% in the fourth quarter. AQR Capital Management LLC now owns 1,168,090 shares of the insurance provider’s stock valued at $428,129,000 after buying an additional 841,298 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: What are the reasons investors use put options?

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.